R-1479

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H12N6O5
Molecular Weight	284.2288
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of R-1479

Structure Search

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O

InChI

InChIKey=ODLGMSQBFONGNG-JVZYCSMKSA-N

InChI=1S/C9H12N6O5/c10-4-1-2-15(8(19)12-4)7-5(17)6(18)9(3-16,20-7)13-14-11/h1-2,5-7,16-18H,3H2,(H2,10,12,19)/t5-,6+,7-,9-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C9H12N6O5
Molecular Weight	284.2288
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:48:30 UTC 2023` Edited by `admin` on `Sat Dec 16 10:48:30 UTC 2023`
Record UNII	M71RA9DMGJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

R-1479

Code

English

R1479

Code

English

4'-C-AZIDOCYTIDINE

Systematic Name

English

4'-AZIDOCYTIDINE

Systematic Name

English

4-AMINO-1-((2R,3R,4S,5R)-3,4-DIHYDROXY-5-(HYDROXYMETHYL)-5-((IMINO-$L^5-AZANYLIDENE)AMINO)TETRAHYDROFURAN-2-YL)PYRIMIDIN-2-ONE

Systematic Name

English

CYTIDINE, 4'-C-AZIDO-

Systematic Name

English

Code System Code Type Description

MANUFACTURER PRODUCT INFORMATION

R-1479

Created by admin on Sat Dec 16 10:48:31 UTC 2023 , Edited by admin on Sat Dec 16 10:48:31 UTC 2023

PRIMARY

Target: HCV; In vitro: R1479 (4'-azidocytidine) is a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC(50) = 1.28 microM) with similar potency compared with 2'-C-methylcytidine (IC(50) = 1.13 microM). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mM. HCV replicon RNA could be fully cleared from replicon cells after prolonged incubation with R1479.; In vivo:Toxicity: R1479 displayed good activity in the replicon assay with no measurable cytotoxic or cytostatic effect.; Clinical trial: A Study of Balapiravir in Patients With Dengue Virus Infection. Phase 1

CAS

478182-28-4

Created by admin on Sat Dec 16 10:48:31 UTC 2023 , Edited by admin on Sat Dec 16 10:48:31 UTC 2023

PRIMARY

PUBCHEM

457388

Created by admin on Sat Dec 16 10:48:31 UTC 2023 , Edited by admin on Sat Dec 16 10:48:31 UTC 2023

PRIMARY

FDA UNII

M71RA9DMGJ

Created by admin on Sat Dec 16 10:48:31 UTC 2023 , Edited by admin on Sat Dec 16 10:48:31 UTC 2023

PRIMARY

EPA CompTox

DTXSID80332457

Created by admin on Sat Dec 16 10:48:31 UTC 2023 , Edited by admin on Sat Dec 16 10:48:31 UTC 2023

PRIMARY

Related Record Type Details


					QI56415283

HEPATITIS C VIRUS

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					VOT0LP7I9K

PRODRUG -> METABOLITE ACTIVE

Amount:

Related Record Type Details


					M71RA9DMGJ

R-1479

ACTIVE MOIETY

Comments:

Hepatitis C virus (HCV) polymerase activity is essential for HCV replication. Targeted screening of nucleoside analogs identified R1479 (4-azidocytidine) as a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50 = 1.28 .MU.m) with similar potency compared with 2-C-methylcytidine (IC50 = 1.13 .MU.m). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mm.

Amount: